Oscient Files Patent Suit Over Cholesterol Drug

Law360, New York (January 15, 2009, 12:00 AM EST) -- Oscient Pharmaceuticals Corp. and Ethypharm SA have launched a patent infringement lawsuit against Lupin Ltd. over the cholesterol drug Antara.

The lawsuit, filed Wednesday in the U.S. District Court for the District of Maryland, was a response to a Paragraph IV certification notice Oscient received last month notifying it that Lupin had filed an abbreviated new drug application with the U.S. Food and Drug Administration seeking agency authorization to market a generic version of Antara.

Lupin is looking to sell generic Antara before the patent covering...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.